SCHEMBL12220125

SCHEMBL12220125

O=C(Nc1cccc2c(=O)cc(-c3ccccc3Cl)oc12)c1cscn1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.52
▸ RECQL P46063 1/20 0.50
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ GPR35 Q9HC97 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ CYP1A1 P04798 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP1B1 Q16678 1/20 0.48
▸ GRM1 Q13255 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CCNA2 P20248 2/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ CCNA1 P78396 2/20 0.45
▸ GRM4 Q14833 1/20 0.43
▸ PIM1 P11309 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12220166 0.90 GPR35 (0.48) GPR35GRM1GRM4PIM1NPC1
SCHEMBL12220086 0.89 GPR35 (0.48) GPR35GRM1KDM4EPIM1NPC1
SCHEMBL12220116 0.89 GPR35 (0.48) MAPTRECQLMEN1KMT2AGPR35
SCHEMBL12220021 0.89 GPR35 (0.48) MAPTRECQLMEN1KMT2AGPR35
SCHEMBL12220146 0.89 MEN1 (0.46) MAPTRECQLMEN1KMT2AGPR35
SCHEMBL12220141 0.88 GPR35 (0.44) MAPTRECQLMEN1KMT2AGPR35
SCHEMBL12220135 0.88 GPR35 (0.48) GPR35GRM1
SCHEMBL12219989 0.87 GPR35 (0.53) MAPTMEN1KMT2AGPR35HPGD
SCHEMBL12220050 0.87 HSD17B10 (0.56) MAPTMEN1KMT2AGPR35HPGD
SCHEMBL2148964 0.87 GPR35 (0.46) MAPTRECQLMEN1KMT2AGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150148343-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS GlaxoSmithKline, LLC 2015-05-28 — — US disclosed
US-20150148343-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS GlaxoSmithKline, LLC 2015-05-28 — — US disclosed
US-8987258-B2 Chromenone analogs as sirtuin modulators GLAXOSMITHKLINE LLC 2015-03-24 — — US disclosed
US-8987258-B2 Chromenone analogs as sirtuin modulators GLAXOSMITHKLINE LLC 2015-03-24 — — US disclosed
EP-2342188-B1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-07-30 — — EP disclosed
US-20110257174-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-10-20 — — US disclosed
US-20110257174-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-10-20 — — US disclosed
WO-2010037127-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257174-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MAPT 1209/4885RECQL 916/4885MEN1 3518/4885
US-20150148343-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MAPT 1321/4885RECQL 968/4885MEN1 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback